Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Apellis Pharmaceuticals (APLS) PT Lowered to $75 at Raymond James
March 3, 2025 7:56 AM ESTRaymond James analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $75.00 (from $78.00) while maintaining a Strong Buy rating.
The analyst comments "We reiterate our Strong Buy rating on APLS following 4Q24 earnings. Given sales were pre-announced during JPM (see our... More
